Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27779376 | 0.88 | NR1H2 (0.36) | NR1H2LIPGHDAC4ESR2DPP4 | |
| SCHEMBL27779222 | 0.86 | NR1H2 (0.37) | NR1H2LIPGHDAC4ESR2DPP4 | |
| SCHEMBL27779496 | 0.85 | NR1H2 (0.37) | NR1H2LIPGHDAC4ESR2DPP4 | |
| SCHEMBL13175269 | 0.85 | NR1H2 (0.44) | NR1H2LIPGHDAC4ESR2DPP4 | |
| SCHEMBL27800696 | 0.84 | NR1H2 (0.36) | NR1H2LIPGHDAC4DPP4MAPT | |
| SCHEMBL2860794 | 0.84 | DPP4 (0.53) | NR1H2LIPGHDAC4ESR2DPP4 | |
| SCHEMBL2863171 | 0.84 | DPP4 (0.41) | NR1H2LIPGHDAC4ESR2DPP4 | |
| SCHEMBL2856421 | 0.84 | LIPG (0.42) | NR1H2LIPGHDAC4ESR2DPP4 | |
| SCHEMBL27800665 | 0.84 | GRIA1 (0.41) | NR1H2LIPGHDAC4KCNH2 | |
| SCHEMBL27779511 | 0.83 | CYP8B1 (0.34) | NR1H2LIPGHDAC4ESR2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113474346-B | Compositions for inhibiting ubiquitin-specific protease 1 | 福马治疗有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20220073525-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3902802-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | Forma Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020139988-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139988-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-8207161-B2 | Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2012-06-26 | — | — | US | disclosed |
| US-8207161-B2 | Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2012-06-26 | — | — | US | disclosed |
| US-8207161-B2 | Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2012-06-26 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| EP-2230241-A1 | TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-09-22 | — | — | EP | disclosed |
| CN-101641361-A | Tetrahydroimidazo [1, 5-a ] pyrazine derivative, preparation method and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD | 2010-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP3, DPP7 | NR1H2 2937/4885LIPG 2955/4885HDAC4 758/4885 |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | PARP1, PARP2, PARP3 | NR1H2 2188/4885LIPG 2321/4885HDAC4 49/4885 |
| US-20220073525-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | USP1, USP2, USP3 | NR1H2 3340/4885LIPG 1497/4885HDAC4 1254/4885 |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | NR1H2 3996/4885LIPG 2941/4885HDAC4 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.